Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Umbilical cord blood CD34+ hematopoietic stem cell-derived natural killer cells in Acute Myeloid Leukemia – a phase I clinical study

View Full Paper
Ask AI
Bookmark
Share

Authors

ASAdrian SchwarzerWFWalter FiedlerDLDavid de Leeuw

Discussion

Loading...

Member takes

Overview

Phase I clinical trial showed safety of cryopreserved NK cells in AML patients, suggesting potential for future treatments.

Key Points

  • NK cell therapy demonstrated safety in acute myeloid leukemia, with no related adverse events reported.
  • Among 16 patients, 41% achieved measurable residual disease negativity after treatment, highlighting efficacy.
  • Analysis utilized variant allele frequencies to evaluate treatment response in acute myeloid leukemia patients.
  • Results support potential for dose expansion with hematopoietic stem cell-derived natural killer cells in future studies.

Cite This Study

Schwarzer et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e473https://doi.org/10.1182/blood-2025-1640
View Full Paper
Ask AI
Bookmark
Share